Advaxis ADXS announced that ADXS-cHER2, its proprietary
immunotherapy for the treatment of breast cancer and canine
osteosarcoma, was featured on ABC News in an article titled “Bone
Cancer Vaccine for Dogs Shows Promise for Breast Cancer”.
Advaxis sponsored a Phase 1 canine osteosarcoma study, conducted by Dr.
Nicola Mason at the University of Pennsylvania School of Veterinary
Medicine, evaluating the safety and efficacy of Advaxis' proprietary
immunotherapy, ADXS-cHER2, in companion dogs. The study has shown that
the dogs that received the Advaxis immunotherapy are living
significantly longer than the dogs whose owners elected not to
participate in
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in